Avalyn Pharma Inc. (AVLN)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Avalyn Pharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Schafer Police & Firemen's Retirement System of New Jersey | 5,052 | $146,406.96 | $145,447.08 | -$959.88 | -0.66% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 2,064 | $59,814.72 | $70,010.88 | $10,196.16 | 17.05% |
Avalyn Pharma Inc. (AVLN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Avalyn Pharma Inc. ever had a stock split?
Avalyn Pharma Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Lyn Baranowski CEO | NASDAQ (NMS) Exchange | 05348Y105 CUSIP |
| US Country | 50 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Avalyn Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative inhaled therapies aimed at treating rare respiratory diseases. Founded on May 27, 2011, by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar, the company is based in Boston, MA. Avalyn focuses on addressing significant unmet medical needs related to pulmonary fibrosis and other interstitial lung diseases (ILDs), which pose considerable challenges for patients and healthcare providers alike. By leveraging advanced inhalation technology, Avalyn aims to improve the delivery and efficacy of treatment options within this specialized therapeutic area.
Products and Services
- AV-101:
AV-101 is a proprietary inhaled therapy currently under development for the treatment of patients suffering from pulmonary fibrosis. Designed to target the lungs directly, AV-101 aims to provide enhanced therapeutic benefits with improved safety profiles compared to systemic treatments. Its formulation is intended to deliver medication effectively, minimizing side effects and enhancing patient quality of life.
- Clinical Trials:
Avalyn Pharma conducts rigorous clinical trials to evaluate the safety and efficacy of its therapeutic candidates. These trials are critical for advancing the development of inhaled medications for interstitial lung diseases. By engaging with regulatory authorities, Avalyn strives to bring innovative treatments to market that can significantly alter the treatment landscape for rare respiratory conditions.
- Research and Development:
The company invests heavily in research and development to expand its pipeline of potential therapies. Avalyn collaborates with leading scientists and research institutions to explore novel inhalation technologies and improve drug formulations, enabling the targeted delivery of medications to the lungs.
- Patient Support Programs:
Avalyn Pharma understands the challenges faced by patients with rare respiratory diseases and is committed to providing comprehensive support. This includes educational resources, access to clinical trial information, and assistance in navigating healthcare options to empower patients in their treatment journeys.
